|
COVID-19 infection
|
|
Asymptomatic
|
675
|
17.8
|
|
Mild
|
658
|
17.3
|
|
Severe
|
1736
|
45.7
|
|
Critical
|
689
|
18.1
|
|
Unknown
|
43
|
1.1
|
|
COVID-19 test samplea
|
|
BAL
|
60
|
1.6
|
|
SARS-CoV-2 nasopharyngeal swab
|
3700
|
97.3
|
|
SARS-CoV-2 serology
|
86
|
2.3
|
|
Reason for COVID-19 testa
|
|
Pulmonary symptoms
|
1454
|
38.3
|
|
Pulmonary + extrapulmonary symptoms
|
831
|
21.9
|
|
Extrapulmonary symptoms
|
742
|
19.5
|
|
Screening
|
727
|
19.1
|
|
Unknown
|
47
|
1.2
|
|
Neutrophils level at COVID-19 diagnosisb
|
|
≤ 0.5 × 109/mm3
|
280
|
7.4
|
|
0.501–0.999 × 109/mm3
|
217
|
5.7
|
|
≥ 1 × 109/mm3
|
2738
|
72.0
|
|
Lymphocytes level at COVID-19 diagnosisb
|
|
≤ 0.2 × 109/mm3
|
344
|
9.1
|
|
0.201–0.499 × 109/mm3
|
538
|
14.2
|
|
≥ 0.5 × 109/mm3
|
2367
|
62.3
|
|
Stay during COVID-19
|
|
Admitted to hospital
|
2778
|
73.1
|
|
Length of hospital stay, median (IQR) [range]
|
15 (8–27), [1–235]
|
–
|
|
ICU
|
689
|
18.1
|
|
Length of ICU stay, median (IQR) [range]
|
11 (5–20), [1–111]
|
–
|
|
Invasive MV
|
449
|
11.8
|
|
Non-invasive MV
|
221
|
5.8
|
|
Clinical outcome of COVID-19
|
|
Death
|
1185
|
31.2
|
|
Observation time, median (IQR) [range]
|
89 (21–172), [0–436]
|
–
|
|
Reason for deatha
|
|
Not related to COVID-19
|
125
|
3.3
|
|
Contributable by COVID-19
|
155
|
4.1
|
|
Attributable to COVID-19
|
843
|
22.2
|
|
Attributable to HM
|
328
|
8.6
|
|
Death due to other reasons
|
123
|
3.2
|
|
Death due to unknown reasons
|
78
|
2.1
|
